ReviewFrontiers in immunology2025
Immunometabolic editing of the tumor microenvironment: from reprogramming mechanisms to therapeutic vulnerabilities.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Metabolic convergence of diabetes and prostate cancer: from dysglycemia to tumor microenvironment reprogramming.Mammalian genome : official journal of the International Mammalian Genome Society · 2026Review
- Chemical priming potentiates mesothelin-targeting chimeric antigen receptor-engineered NK-92 antitumor activity by improving tumor trafficking and cytotoxic killing dynamics.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic reprogramming is not only one of the malignant characteristics of tumor cells, but also commonly seen in a variety of immune cells in tumor microenvironment(TME), which massively promotes tumor-body immune interaction. Immunometabolic editing is a dynamic, co-evolutionary process wherein adaptive metabolic reprogramming in the TME, driven by tumor-immune crosstalk during immunoediting, critically shapes anti-tumor immune response and governs immune evasion. Studies of metabolic pathways linked to anti-tumor immune process and discoveries of important therapeutic targets are conducive to the development of targeted immunometabolic intervention to enhance the body's anti-tumor immune response and improve the efficacy of tumor immunotherapies. This review summarizes metabolic characteristics of the TME, highlights immunometabolic editing during cancer evolution, and discusses mechanisms by which tumor immunotherapies modulate tumor immunometabolism to identify potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.